SCHEDULE: Jorey Chernett Discloses 5.01% Stake in Lineage Cell

Jorey Chernett has reported beneficial ownership of 5.01% of Lineage Cell Therapeutics, Inc.'s common stock, totaling 11,445,003 shares.

Summary

• Jorey Chernett has filed a Schedule 13G, indicating beneficial ownership of common stock in Lineage Cell Therapeutics, Inc.
• The filing reports ownership of 11,445,003 shares of common stock.
• This ownership represents 5.01% of the total outstanding common stock of Lineage Cell Therapeutics, Inc.
• The shares are held with sole voting power and sole dispositive power.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership, indicating a neutral sentiment. It does not contain performance results or forward-looking statements that would typically influence sentiment.

Positives

• The disclosure of a new significant shareholder, Jorey Chernett, holding over 5% of common stock, can be viewed as a vote of confidence in Lineage Cell Therapeutics, Inc.

Future Outlook

NA

Industry Context

Lineage Cell Therapeutics, Inc. operates in the biotechnology sector, focusing on cell therapies. The disclosure of a significant passive stake by an individual investor is a routine transparency event in this industry, providing insight into major shareholder positions.

Stakeholder Impact

• Shareholders gain increased transparency regarding the ownership structure of Lineage Cell Therapeutics, Inc. with the disclosure of a new significant individual investor.

Key Dates

Keywords

Lineage Cell Therapeutics, Jorey Chernett, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Biotechnology, Investment